About the Conference
The American Society for Transplantation and Cellular Therapy (ASTCT)/The European Society for Blood and Marrow Transplantation (EBMT) are proud to present the ASTCT+EBMT 7th International Conference on Relapse after Transplant and Cellular Therapy.
Hematopoietic stem cell transplantation and cellular therapy (HSCT2) are life-saving treatment options for many hematologic malignancies and some solid tumours. Relapse and disease progression are the leading causes of treatment failure for most hematologic malignancies treated with both allogeneic and autologous hematopoietic stem cell transplantation (HSCT) and also CAR T cell therapy. Since the first symposium, more than 12 years ago, we have witnessed tremendous progress in our understanding and treatment of relapse including the development of therapies specifically licensed to treat or prevent relapse post HSCT and cellular therapies.
The conference will feature internationally recognized speakers from a multidisciplinary, diverse group comprised of basic and translational scientists and clinical investigators. The conference will include formal didactic presentations and informal discussion panels. It will also offer investigators interested in the field the opportunity to present their work in dedicated oral and poster sessions. As in previous years, abstracts will be selected for oral presentation in the meeting.
The planned objectives of the 7th International Conference are designed to present the latest scientific and clinical advances related to relapse after HSCT and to provide a forum for the presentation of ongoing laboratory, translational, and clinical research specifically related to this field.
The goals of the conference are to review the state of the science and basic, translational and clinical research related to relapse after allogeneic and autologous HSCT, along with cellular therapies.
- Update the current state of the science relative to biology and clinical study of relapse related to autologous and allogeneic HSCT, along with cellular therapies.
- Provide a forum for the presentation of ongoing laboratory and translational research specifically related to relapse following HSCT or cellular therapy.
- Provide a forum to present ongoing clinical trials that are specific to the study of and treatment of relapse following HSCT or cellular therapy.
- Provide an overview of the potential role of CAR T cells and other cellular therapies in the prevention and treatment of relapse following HSCT.
Who Should Attend
- Medical and pediatric hematologists oncologists
- Translational and basic scientists
- Hematopathologists, physicians-in-training (Fellows/Residents/Post Docs)
- Advance practice providers,
- Pharmacists, oncology nurses
- Other associated allied health professionals